Reprogramming Cellular Behavior with RNA Controllers Responsive to Endogenous Proteins by Culler, Stephanie J. et al.
www.sciencemag.org/cgi/content/full/330/6008/1251/DC1 
 
 
 
 
 
 
Supporting Online Material for 
 
Reprogramming Cellular Behavior with RNA Controllers Responsive to 
Endogenous Proteins 
Stephanie J. Culler, Kevin G. Hoff, Christina D. Smolke* 
*To whom correspondence should be addressed. E-mail: csmolke@stanford.edu 
 
Published 26 November 2010, Science 330, 1251 (2010) 
DOI: 10.1126/science.1192128 
 
This PDF file includes: 
 
Materials and Methods 
SOM Text 
Figs. S1 to S9 
Tables S1 to S10 
References 
 
2 
 
Materials and Methods 
Construction of RNA device plasmids 
The SMN1-GFP mini-gene fusion plasmid (pCS1773) was constructed through PCR 
amplification, digestion and ligation in the appropriate expression vector. A region 
encompassing the last nine nucleotides of exons 6 through the first 21 nucleotides of exon 8 of 
the SMN1 mini-gene (S1) was amplified through PCR from template pCS1774 with primers Ex6 
and Ex8 and PfuUltra II fusion high-fidelity DNA polymerase (Stratagene) and the resulting 
PCR product was digested with NheI. The SMN1 mini-gene DNA synthesis was performed by 
DNA 2.0 to contain restriction sites KpnI, EcoRV, ClaI (positions -87, -61 and -50 from 3’ ss of 
exon 7, respectively) and XhoI, HindIII, BamHI and XbaI (positions +10, +50, +70 and +97 
from 5’ ss of exon 7, respectively). The GFP gene was amplified from the template pKW430 
(S2) with primers GFP1 and GFP2. The resulting PCR product was digested with ApaI and NheI 
and ligated into the corresponding restriction sites of the mammalian expression vector 
pcDNA5/FRT (Invitrogen). The SMN1 mini-gene PCR product was then ligated into the NheI 
restriction site of the resulting GFP construct, to construct the base plasmid SMN1-GFP. The 
aptamer sequences used in this study are CGTACACCATCAGGGTACG (S3) for MS2; 
CGTACCCATCAGGGTACG (lacks a bulged adenosine required for MS2 binding) (S3, S4) for 
MS2∆; AGGCCGATCTATGGACGCTATAGGCACACCGGATACTTTAACGATTGGCT 
(S5) for β-catenin; TCGGTTAGCAATTTCATAGGCCACACGGATATCGCAGGTATCTAGC 
CGGA (reverse compliment) for β-catenin∆; GCATCCTGAAACTGTTTTAAGGTTGGCCGA 
TGC (S6) for NF-κB p50(1); CGTAGCCGGTTGGAATTTTGTCAAAGTCCTACG (reverse 
compliment) for NF-κB p50(1)∆ and p50(2)∆; GATCTTGAAACTGTTTTAAGGTTGGCCGA 
TC (S7) for NF-κB p50(2); GAAGCTTACAAGAAGGACAGCACGAATAAAACCTGCGTAA 
ATCCGCCCCATTTGTGTAAGGGTAGTGGGTCGAATTCCGCTCA (S8) for NF-κB p65; 
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ACTCGCCTTAAGCTGGGTGATGGGAATGTGTTTACCCCGCCTAAATGCGTCCAAAAT 
AAGCACGACAGGAAGAACATTCGAAG (reverse compliment) for NF-κB p65∆. 
Aptamer and mutant cassette sequences containing portions of the SMN1 mini-gene were 
digested and ligated into the appropriate restriction sites within the SMN1-GFP plasmid (Table 
S8). Briefly, oligonucleotides encoding the forward and reverse strands of the wild-type and 
mutant MS2 coat protein aptamers were annealed, digested with the appropriate restriction 
enzymes and ligated into SMN1-GFP. β-catenin aptamer constructs were generated through PCR 
using the oligonucleotide cassette templates β-cat-3, β-cat∆-3, β-cat-6, and β-cat∆-6 (Table S9) 
and reverse primer AptRv with forward primers Bcat3, Bcat∆3, Bcat6, and Bcat∆6, respectively 
(Table S7). Similarly, for the NF-κB p50 and p65 aptamer constructs, the oligonucleotide 
cassette templates NF-κBp50(1)-3, NF-κBp50(1)∆-3, NF-κBp50(2)-3, NF-κBp65-3, and NF-
κBp65∆-3 were PCR amplified with reverse primer AptRv and forward primers p50(1), p50(1)∆, 
p50(2), and p65, respectively. The resulting β-catenin, NF-κB p50 and p65 wild-type and mutant 
PCR products were digested with the appropriate restriction enzymes and ligated into the 
corresponding restriction sites of SMN1-GFP (pCS1775-pCS1783, Table S8). To construct the 
multi-input RNA devices containing the wild-type and mutant MS2 coat protein aptamers in 
positions 3 and 10, the MS2-3 and MS2∆ -3 annealed cassettes were digested with EcoRV and 
XhoI and ligated into the corresponding restriction sites of SMN1-GFP containing the wild-type 
and mutant MS2 coat protein aptamers in position 10 (pCS1784-pCS1787, Table S8). To 
construct the multi-input RNA devices containing the wild-type and mutant NF-κB p65 aptamers 
in position 3 and the wild-type and mutant MS2 coat protein aptamers, the NF-κB p65 PCR 
products were digested with EcoRV and Xho I and ligated into the corresponding restriction sites 
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of SMN1-GFP containing the wild-type and mutant MS2 coat protein aptamers in position 10 
(pCS1788-pCS1791, Table S8). 
The SMN1-Puma and SMN1-TK fusion plasmids were constructed in two steps. The 
human Puma gene was amplified from pORF5-hPUMA (Invivogen) with primers Puma1 and 
Puma2 designed to place a flexible Gly-Ser linker (GGSGGS) at the 5’ end of the gene. The 
resulting PCR product was digested with NheI and PmeI and ligated into the corresponding 
restriction sites of pcDNA5/FRT to construct the plasmid pCS1792. The SMN1-GFP constructs 
pCS1793-pCS1794, pCS1777-pCS1778, pCS1782-pCS1783 were digested with NheI and the 
resulting SMN1 mini-genes were ligated into the corresponding restriction site in pCS1773, 
resulting in plasmids MS2-3-Puma, MS2∆-3-Puma, β-cat-6-Puma, β-cat∆-6-Puma, p65-3-Puma, 
and p65∆ -3-Puma (pCS1795-pCS1800, Table S8). Similarly, to construct the SMN1-TK 
plasmids the HSV-TK gene was amplified from pCD19t-Tk-T2A-IL15op_epHIV7 (a generous 
gift from M. Jensen, City of Hope) using primers TK1 and TK2. The resulting PCR product was 
digested with NheI and PmeI and ligated into corresponding restriction sites of pcDNA5/FRT 
creating pCS1801. The NheI digested SMN1 mini-genes from pCS1777-pCS1778 and pCS1782-
pCS1783 were ligated into the corresponding restriction site of pCS1801, resulting in plasmids 
β-cat-6-TK, β-cat∆-6-TK, p65-3-TK, and p65∆-3-TK (pCS1802-pCS1805, Table S8). 
To construct the MS2-DsRed expression plasmid (pCS1392), the DsRed monomer gene 
was amplified from pDsRed-monomer (Clontech) with primers DsRed1 and DsRed2, digested 
with BamHI and NotI and ligated into the corresponding restriction sites of pcDNA5/FRT 
creating pCS489. The MS2 coat protein gene was amplified in two steps from template pHis-
BIVT-MS2-RSp55 (S9) using primers MS2-1 and MS2-2 for the first round and MS2-3 and 
MS2-2 for the second round to fuse a FLAG epitope (DYKDDDDK) (S10) followed by an SV40 
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NLS (PKKKRKV) (S11), to the 5’ end of the MS2 coat protein gene. The final PCR product was 
digested with KpnI and BamHI and ligated into the corresponding restriction sites of pCS489. 
The p50-DsRed expression plasmid (pCS1806) was constructed similarly, where the p50 gene 
was amplified in two steps from template pGAD424 (S12) using primers p50-1 and p50-2 for the 
first round and p50-3 and p50-2 for the second round to fuse a FLAG epitope followed by a 
SV40 NLS to the 5’ end of the p50 gene. The final PCR product was digested with NheI and 
KpnI and ligated into the corresponding restriction sites pCS489. 
To construct the MS2-Venus expression plasmid (pCS1806), the construct pCS2/Venus 
(S13) was digested with BamHI and ApaI and the resulting venus gene was ligated into the 
corresponding restriction sites of pcDNA5/FRT creating pCS1807. pCS1392 was digested with 
KpnI and BamHI and the resulting FLAG-NLS-MS2 fragment was ligated into the 
corresponding restriction sites of pCS1807. Venus was chosen as our fluorescent reporter for the 
MS2 induced apoptosis studies (Fig. S5A and B) to avoid significant spectral overlap with the 7-
aminoactinomycin D (7AAD) viability dye. 
 
Cell culture, transfections, stable cell lines, and flow cytometry analysis 
All cell culture media was obtained from Invitrogen. Isogenic HEK-293 stable cell lines were 
generated by co-transfection of the appropriate RNA device construct and a plasmid encoding 
the Flp recombinase (pOG44) in HEK-293 FLP-In cells grown in medium without Zeocin 
according to the manufacturer’s instructions (Invitrogen). Stable selections were carried out in 6-
well plates seeded with ~2x105 HEK-293 FLP-In cells per well, where 1.8 µg of pOG44 and .2 
µg of the RNA device construct (10:1 ratio) were co-transfected. Fresh medium was added to the 
cells 24 h after transfection. The cells were expanded by a 1:4 dilution and Hygromycin B was 
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added to a final concentration of 200 μg/ml 48 h after transfection. Clones were harvested by 
trypsinization, pooled, and analyzed using a Quanta Cell Lab Cytometer (Beckman Coulter; 
Fullerton, CA) 10-14 days after transfection. Flow cytometry data was analyzed using the 
FlowJo v.7.1 (Tree Star, Inc.) software package. Flow cytometry analysis and gating procedures 
for all regulatory devices is presented in Figs. S6 to S9. 
For transient transfection studies, HEK-293 cell lines stably expressing the RNA devices 
were seeded in 24-well plates at ~5x104 cells per well 16 to 24 h prior to transfection. Cell lines 
were transfected with 250 ng of the appropriate MS2-DsRed, MS2-Venus, p50-DsRed, DsRed, 
or Venus expression constructs. The cells were harvested by trypsinization, pooled, and analyzed 
by flow cytometry and microscopy 48 h after transfection. All presented microscopy images 
were taken during an individual experiment. GFP and DsRed fluorescence, as measured by flow 
cytometry, was excited at 488 nm and emission was measured through a 525-nm filter and a 610-
nm band-pass filter, respectively. Experiments were carried out on different days and 
transfections were completed in duplicate, where the mean GFP fluorescence of the DsRed 
viable transfected population was evaluated. GFP fluorescence levels of both the wild-type and 
mutant RNA devices in the presence of ligand were normalized to the GFP fluorescence of the 
cell lines in the absence of ligand. Relative expression (fold) data is reported as the normalized 
mean fluorescence for each wild-type sample divided by the normalized mean fluorescence for 
each mutant sample + the average error. 
For the induction of the Wnt and NF-κB pathways, HEK-293 cell lines stably expressing 
the RNA devices were seeded in a 24-well plate at ~5x104 cells per well 16 to 24 h prior to 
induction with LTD4 or TNF-α. Cells were treated with 20 ng/mL TNF-α (Sigma) for 48 h for 
the NF-κB pathway induction studies (S14). For the Wnt pathway induction studies, cells were 
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serum starved 2 h before stimulation with 80 nM leukotriene D4 (LTD4) (Sigma) for 48 h in the 
absence of serum (S15). After stimulation of either pathway, the cells were harvested by 
trypsinization, pooled and analyzed by flow cytometry and microscopy. GFP fluorescence as 
measured by flow cytometry was excited at 488 nm and emission was measured through a 525-
nm filter band-pass filter. Both microscopy and flow cytometry experiments were carried out on 
different days and were completed in duplicate, where the mean GFP fluorescence of the viable 
cell population and the average error between samples is reported. GFP fluorescence levels of 
both the wild-type and mutant RNA devices in the presence of ligand were normalized to the 
GFP fluorescence of the cell lines in the absence of ligand. Relative expression (fold) data is 
reported as the normalized mean fluorescence for each wild-type sample divided by the 
normalized mean fluorescence for each mutant sample + the average error. 
 
Apoptosis assays 
Stable cell lines were harvested by trypsinization as described above. For the Puma apoptosis 
studies, cell lines stably expressing the RNA devices were seeded in a 24-well plate at ~5x104 
cells per well 16 to 24 h prior to induction with LTD4 or TNF-α or transfection with 250 ng of 
MS2-Venus or Venus alone as described above. 48 h after transfection or induction, the pooled 
cells were washed in cold phosphate-buffered saline (PBS). Cells were stained with Pacific blue 
annexin V and 7AAD using the Vybrant Apoptosis Assay Kit (Invitrogen) according to the 
manufacturer’s instructions. The fluorescence of the stained cells was measured using a Quanta 
Cell Lab Cytometer, where the Pacific blue dye was excited using a UV light source and 
measured through a 465/430 band-pass filter (FL1). Venus and 7AAD were excited with a 488-
nm laser and measured through a 535-nm band-pass (FL2) and 670-nm long pass filter (FL3) 
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respectively. In this assay, live cells are annexin V negative and 7AAD negative, apoptotic cells 
are annexin V positive and 7AAD negative and dead cells are annexin V negative and 7AAD 
positive. Experiments were carried out on different days and transfections/inductions were 
completed in duplicate. For the MS2-Puma device studies the mean percentage of cells 
undergoing apoptosis (annexin V positive and 7AAD negative) within the Venus positive 
population + the average error is reported. For the NF-κB and Wnt signaling devices fused to 
Puma, the mean percentage of cells undergoing apoptosis (annexin V positive and 7AAD 
negative) + the average error is reported. Flow cytometry analysis and gating procedures for all 
apoptosis-inducing regulatory devices is presented in Figs. S8 and S9. 
For the ganciclovir (GCV) sensitivity assays, HEK-293 cell lines stably expressing the 
RNA devices were seeded in a 24-well plate at ~5x104 cells per well 16 to 24 h prior to induction 
with LTD4 or TNF-α. At the time of induction cells were either left untreated or incubated with 
different concentrations of GCV (10 or 100 µg/ml). After 96 h the cells were harvested by 
trypsinization, pooled and analyzed by flow cytometry and microscopy. For these studies, the 
mean percentage of alive cells (7AAD negative) + the average error is reported. 
 
qRT-PCR analysis 
Total cellular RNA was purified from stably transfected HEK-293 Flp-In cells using GenElute 
mammalian total RNA purification kit (Sigma) according to the manufacturer’s instructions, 
followed by DNase treatment (Invitrogen). cDNA was synthesized using a gene-specific primer 
for the pcDNA5/FRT vector (SMN1cDNA) and Superscript III reverse transcriptase (Invitrogen) 
according to the manufacturer’s instructions. qRT-PCR analysis was performed using isoform-
specific primers (Table S10) where each reaction contained 1 µL template cDNA, 10 pmol of 
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each primer, and 1X iQ SYBR green supermix (BioRAD) to a final volume of 25 µL. Reactions 
were carried out using a iCycler iQ system (BioRAD) for 30 cycles (95ºC for 15 s, 72ºC for 30 
s). The purity of the PCR products was determined by melt curve analysis. Data analysis was 
completed using the iCycler IQ system software v.3.1.7050 (BioRAD). Isoform-specific relative 
expression was calculated using the ∆Ct (change in cycling threshold) (S16). Expression levels 
of duplicate PCR samples were normalized to the levels of HPRT (Hypoxanthine-guanine 
phosphoribosyltransferase). Unless otherwise noted, data is reported as the ratio of the mean 
expression levels of the exon 7 excluded isoform to the exon 7 included isoform for the wild-
type device relative to the same ratio for the mutant control device under the indicated ligand 
condition + the average error. 
 
Statistical Analysis 
Data are expressed as relative expression (fold) or expression (fold) + average error where 
applicable. Relative expression (fold) is taken to be: [(device response (+ligand))/(device 
response (-ligand))]/[(mutant device response (+ligand))/(mutant device response (-ligand))] or is 
the ratio of the expression of the wild-type device in the presence of ligand to the absence of 
ligand, normalized to the same ratio for the mutant RNA device. Expression (fold) is the ratio of 
the expression of the RNA device in the presence of ligand to the absence of ligand. Relative 
expression is the ratio of the expression of the wild-type device to the mutant device under the 
same condition. Student’s t-test and Anova analyses were performed using Microsoft Excel. P < 
0.05 were taken to be significant. 
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Supporting Text 
Text S1: Data Reporting Methods and Controls 
Gene expression can be sensitive to a myriad of external factors, such that appropriate controls 
are required to account for potential nonspecific effects of experimental procedures applied to 
cells. For example, gene expression activity measured through fluorescent reporters can be 
altered through nonspecific effects of the ligand on gene expression or cellular fluorescence 
through other cellular mechanisms. We conducted careful controls in the experiments reported in 
this study to ensure accurate accounting of any nonspecific effects of heterologous protein 
expression or exogenous ligand addition (when inducing pathway signaling) on gene expression 
and phenotypic responses (cell survival and death). 
 For each aptamer-containing device, a corresponding inactive sensor control (negative 
control) was constructed in which the wild-type aptamer was replaced by a mutated aptamer, 
such that the only difference between the device and its corresponding control was its ability to 
bind to its corresponding ligand. As such, measuring the difference in gene expression (or other 
measure of output activity) in the presence and absence of ligand for the negative control 
provides a measure of nonspecific effects of the ligand. The same measurement for the wild-type 
aptamer device provides a combined measure of specific and nonspecific effects of the ligand on 
the measured device output. To account for the non-aptamer-mediated effects of the ligand, we 
normalize the fold-change (ratio of signal in the presence and absence of ligand) of the wild-type 
device to that of the negative control. As it is assumed that the nonspecific effects of the ligand 
will be similar for a device containing a wild-type aptamer and its negative control, this value 
provides a measure of the specific effects of ligand binding to the sensor element on the gene 
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regulatory output of the device. The validity of such normalization methods for ligand-mediated 
gene-regulatory systems has been previously described (S17). We feel it is particularly useful in 
the systems used in this work as the addition of molecules that activate pathway signaling (i.e., 
TNF-α, LTD4) may have significant nonspecific effects on cellular fluorescence, gene 
expression, or other cellular mechanisms. 
 The device responses are characterized through several different gene expression and 
phenotypic assays, and the reproducible agreement between these characterization methods 
provide further confirmation of their ligand-responsive gene-regulatory activities. Specifically, 
activity measurements based on transcript isoform (assayed through qRT-PCR) and fluorescent 
reporter levels (assayed through flow cytometry) generally agree with one another. In addition, 
for the majority of the devices the characterized device response is apparent in the unnormalized 
data for both fluorescent reporter and transcript isoform levels (Tables S1 to S6). The exception 
to this are for the devices that increase exon inclusion (MS2-6 and the NF-κB p50-responsive 
devices), where unnormalized gene expression data indicate no changes or slight increases in 
GFP levels in the presence of ligand. However, the fold change in GFP levels is significantly 
lower than all devices that increase exon exclusion, and the corresponding unnormalized 
transcript isoform levels support the reported device responses. The transcript isoform levels 
provide a more direct measure of splicing regulation from the devices, whereas cellular 
fluorescence is likely more influenced by any nonspecific effects of the ligands. 
 Finally, the ligand-specific responses of the devices are further supported by phenotypic 
assays that characterize cell survival and cell death within cell populations harboring individual 
devices in the presence and absence of appropriate ligands (Fig. 4). In a therapeutic application 
one would be more concerned with the absolute performance of the device. Therefore, we report 
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absolute measures of cell survival (or death) within a given cell population for the phenotypic 
assays and do not report values normalized to the relevant negative control. The negative 
controls are reported separately to demonstrate the specificity of ligand addition on the resulting 
phenotypic effect to cells harboring the functional devices. These assays demonstrate that the 
RNA devices are able to effectively regulate a phenotypic response in a manner that correlates 
with their characterized gene-regulatory activity. In addition, the data demonstrate that relatively 
moderate gene-regulatory effects (~2-4-fold) can be used to effectively regulate downstream 
functional outputs when linked to potent upstream regulators. This observation is supported by 
other recent work on engineered RNA regulatory systems applied to the regulation of T-cell 
proliferation (S17) and bacterial chemotaxis (S18). 
 
Text S2: Mechanisms by which Protein Binding can Alter Splicing Patterns 
Previous experiments have shown that the binding of antisense oligonucleotides to a transcript 
can either enhance or inhibit the inclusion of an alternatively spliced exon depending on the 
location of binding within the transcript (S19). These studies have shown that oligonucleotide 
binding to the transcript can block key cis-acting signals that act to recruit enhancers, silencers, 
or spliceosomal components. Other experiments have shown that bifunctional antisense 
oligonucleotides, which harbor an antisense region and a binding sequence for a splicing factor, 
can be used to recruit splicing factors to specific transcript locations (S3, S20). Different effects 
on alternative splicing (i.e., exclusion or inclusion) have been observed, depending on the 
identity of the recruited splicing factors (S21, S22).  
These earlier studies support that the recruitment of proteins to a transcript through 
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binding to an integrated aptamer sequence can alter splicing patterns through two different 
mechanisms. First, the recruited protein can hinder the binding of other trans-acting splicing 
factors or spliceosomal components. For example, by hindering the binding of enhancers or 
spliceosomal components protein binding would result in increased exon exclusion, whereas by 
hindering the binding of silencers it would result in increased inclusion. Second, the recruited 
protein may in turn act to recruit other splicing factors to the transcript through protein-protein 
interactions between the protein ligand and the splicing factor. The resulting splicing pattern 
would depend on whether an enhancer or silencer was recruited to the transcript. Therefore, the 
resulting effect of protein binding to the aptamer would be a function of the relative location in 
the transcript (i.e., aptamer location relative to other cis-acting splicing regulatory sequences) 
and the identity of the protein (i.e., any protein-protein interaction domains that would allow the 
protein to recruit other factors that would in turn affect splicing).  
The results described here can be explained in the context of this mechanistic model. 
Position-dependent effects of aptamer integration can be explained by the relative distances of 
the sites from cis-acting splicing sequences, where positions 3, 6, and 10 are located at critical 
distances from the 5’ splice site, the branch point, and the 3’ splice site. In addition, the different 
effects on alternative splicing observed from different protein ligands at identical aptamer 
integration positions (e.g., p50 and p65) can be explained by protein-specific and ligand binding 
properties. For example, p65 may result in increased exon exclusion through steric hindrance of 
an enhancer or spliceosomal component, whereas p50 may result in increased exon inclusion by 
interacting with and recruiting a splicing factor that acts to enhance splicing. The two proteins 
have contrasting structural domains that mediate protein-protein interactions, where p65 has a 
trans-activation domain and p50 has a trans-repression domain (S23). In addition, the affinities of 
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both aptamers for their cognate ligand differ by 2-fold (S8, S24), and the overall conformation 
and size of the protein dimers bound to the RNA aptamers are different.  
Based on this mechanism, we would not expect a small molecule aptamer to control 
alternative splicing in the described platform. Unlike many other synthetic riboswitch platforms, 
the described system does not function through a conformational switching event or stabilization 
of a particular secondary structure through ligand binding, which are mechanisms amenable to 
control through small molecule ligand binding. The described system functions through the 
recruitment of a protein ligand to the transcript, which can them sterically hinder the assembly of 
other trans-acting splicing factors or spliceosomal components or aid in the recruitment of these 
factors. Small molecule ligands would not be able to act through these mechanisms. 
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Figure S1. Additional expression and transcript isoform analysis of the MS-responsive 
devices and nuclear localization of MS2-DsRed/MS2-Venus  
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(A) Transcript isoform analysis of the SMN1-GFP construct (which harbors a natural stop codon 
in the alternatively spliced exon) lacking an aptamer input module with primer sets specific for 
exon 7 excluded and included products demonstrates that the presence of the MS2-DsRed fusion 
protein does not alter splicing patterns. For all qRT-PCR data, expression levels of duplicate 
samples were normalized to the levels of HPRT. Data is reported as the ratio of the mean 
expression levels of the exon 7 excluded isoform to the exon 7 included isoform + the average 
error. Exon inclusion percentages are shown. All error bars represent +/- s.d. from the mean 
values determined from two independent experiments. (B) The integration of the wild-type and 
mutant aptamer input modules can affect the regulatory output of the device. The observed 
effects are consistent between those observed from the wild-type (upper panel) and mutant 
(lower panel) aptamer input modules in the absence of ligand. Activities are reported as relative 
expression by taking the ratio of the mean GFP levels of the indicated RNA device to that from 
the SMN1-GFP construct lacking an aptamer input module as determined from flow cytometry 
analysis. For all reported activities, expression levels were determined by flow cytometry 
analysis from two independent experiments. (C) Transcript isoform analysis of the wild-type 
(upper panel) and mutant (lower panel) MS2-responsive devices. qRT-PCR data supports gene 
expression data (Fig. S1B). Data is reported as the ratio of the mean expression levels of the 
exon 7 excluded isoform to the exon 7 included isoform for the wild-type and mutant devices 
relative to the same ratio for the SMN1-GFP construct lacking an aptamer input module. (D) 
Confocal images of HEK293 Flp-In cells expressing the MS2-DsRed and MS2-Venus fusion 
constructs. The MS2-DsRed and MS2-Venus fusion proteins colocalize with the Hoescht nuclear 
stain in cells transiently expressing the constructs. (E) The response of the MS2-responsive 
device to heterologously expressed MS2-DsRed fusion protein is affected by the location of the 
input module and demonstrates specificity of device response to the wild-type aptamer. 
Activities for the wild-type (light gray bars) and mutant devices (dark gray bars) are reported as 
expression (fold), where the ratio of the mean GFP level of the device in the presence of MS2-
DsRed (presence of ligand) is normalized to the mean GFP level in the presence of DsRed alone 
(absence of ligand). (F) Transcript isoform analysis of the wild-type (upper panel) and mutant 
(lower panel) MS2-responsive devices with primer sets specific for exon 7 excluded (light gray 
bars) and included (dark gray bars) products. Transcript isoform levels are reported as isoform 
levels (fold), where the mean isoform level in the presence of MS2-DsRed (presence of ligand) is 
normalized to the mean isoform level in the presence of DsRed alone (absence of ligand) + the 
average error. 
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Figure S2. Transcript isoform and expression analysis of the NF-κB- and β-catenin-
responsive devices 
(A) Transcript isoform analysis of the wild-type (upper panel) and mutant (lower panel) NF-κB-
responsive devices with primer sets specific for exon 7 excluded (light gray bars) and included 
(dark gray bars) products. Transcript isoform levels are reported as isoform levels (fold), where 
the mean isoform level in the presence of TNF-α (presence of ligand) is normalized to the mean 
isoform level in the presence of water alone (absence of ligand) + the average error. (B) The NF-
κB p50-responsive devices exhibit responses to a heterologously expressed p50-DsRed fusion 
protein similar to that observed with TNF-α stimulation. Activities for the wild-type and mutant 
NF-κB p50-responsive devices are reported as expression (fold), where the mean GFP level of 
the device in the presence of p50-DsRed (presence of ligand) is normalized to the mean GFP 
level in the presence of DsRed alone (absence of ligand). (C) Transcript isoform analysis of the 
wild-type (upper panel) and mutant (lower panel) β-catenin-responsive devices with primer sets 
specific for exon 7 excluded (light gray bars) and included (dark gray bars) products. Transcript 
isoform levels are reported as isoform levels (fold), where the mean isoform level in the presence 
of LTD4 (presence of ligand) is normalized to the mean isoform level in the presence of water 
alone (absence of ligand) + the average error. 
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Figure S3. Transcript isoform analysis of the multi-input processing RNA devices and 
control responses 
(A) Transcript isoform analysis of the MS2 multi-input processing regulatory devices with 
primer sets specific for exon 7 excluded (light gray bars) and included (dark gray bars) products. 
Relative isoform levels (fold) are reported by dividing the mean isoform level in the presence of 
MS2-DsRed (presence of ligand) by the mean isoform level observed with DsRed alone (absence 
of ligand) + the average error, where this ratio is normalized by the corresponding ratio for the 
double mutant control device. Transcript isoform analysis of the MS2 multi-input processing 
devices also supports gene expression data. (B) The MS2 / NF-κB p50 multi-input processing 
device response is specific for the MS2 and NF-κB p50 ligands. Combinations of the NF-κB p50 
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and MS2 aptamers (wild-type and mutant) were inserted into positions 3 and 10, respectively. P-
values derived from the Student’s t-test for all reported activities are as follows: *P < 0.05 and 
**P < 0.01. Relative expression (fold) and relative excl/incl (fold) were determined as described 
in Fig. 1E. (C) Transcript isoform analysis of the MS2 / NF-κB p50 multi-input processing 
devices with primer sets specific for exon 7 excluded (light gray bars) and included (dark gray 
bars) products. 
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Figure S4. Analysis of cell survival in wild-type and stable cell lines expressing HSV-TK 
output module devices 
(A, B) Phase images of the β-catenin- (A) and NF-κB-responsive (B) devices fused to HSV-TK. 
Increased cell death from the β-catenin- and NF-κB-responsive devices is specific to pathway 
stimulation, GCV, and the wild-type aptamers. (C) Dose-response curve of cell survival 
percentages for HEK-293 cells stably expressing HSV-TK from a CMV promoter. Survival 
percentages of cells exposed to GCV (0-100 µg/ml) were assessed by flow cytometry. (D) Dose-
response curve of cell survival percentages for wild-type HEK-293 cells. Survival percentages of 
cells exposed to GCV (0-100 µg/ml) were assessed by flow cytometry. P-values derived from 
the Student’s t-test for all reported activities are as follows: *P < 0.05 and **P < 0.01. 
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Figure S5. Analysis of cell survival/apoptosis percentages in transiently transfected 
HEK293 cells and stable cell lines expressing Puma output module devices 
We replaced the GFP coding sequence with the proapoptotic gene Puma, where the 
overexpression of Puma induces rapid apoptosis (S25). (A) Mechanism of the MS2-responsive 
device fused to an output module that results in apoptosis (Puma). (B) The MS2-responsive 
(MS2-3) device fused to Puma triggers increased levels of apoptosis in cells heterologously 
expressing the MS2-Venus fusion protein. Apoptosis of the wild-type and mutant devices was 
assessed by flow cytometry (as described in Materials and Methods) in the presence of the MS2-
Venus fusion and Venus. For all reported activities, the mean cell survival and apoptosis levels 
from two independent experiments are shown. Cells stably expressing the MS2 device (MS2-3) 
linked to Puma displayed a 50% increase in apoptosis in the presence of a MS2-Venus 
(fluorescent protein) fusion construct compared to cells transfected with Venus alone, whereas 
the mutant MS2 device resulted in an insignificant response (~10%). (C) Flow cytometry 
analysis of cell survival percentages of HEK293 cells alone and in the presence of MS2-DsRed. 
The results demonstrate that HEK293 cells have a high level of cell viability that is not affected 
by transient transfection. (D) Flow cytometry analysis of apoptosis in HEK293 cells stably 
expressing Puma alone. Apoptosis of this cell line was assessed in the presence of the MS2-
Venus fusion and Venus alone. (E, F) Mechanisms of the β-catenin- and NF-κB-responsive 
devices fused to the apoptosis output module (Puma), which trigger apoptosis in response to 
detection of disease markers. The β-catenin- (β-cat-6) and NF-κB p65-responsive (p65-3) 
devices fused to Puma trigger increased levels of apoptosis in cells where signaling has been 
stimulated through these pathways. Stimulation of the β-catenin pathway led to a significant ~2-
fold increase in apoptosis in cells stably expressing the β-cat-6 device (P < 0.01). Cells stably 
expressing the p65-3 devices exhibited a 40% increase in apoptosis in response to TNF-α (P < 
0.05). Apoptosis was assessed by flow cytometry in the presence and absence of the appropriate 
stimulation molecule (TNF-α or LTD4).  
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Figure S6. Flow cytometry analysis and gating procedures for the MS2- and β-catenin-
responsive devices 
(A) Flow cytometry and gating procedure for all MS2-responsive devices. As an example, flow 
cytometry data from the MS2-3 device is presented. Dot plots show initial gating of viable stable 
cells (P1), followed by gating for all MS2-DsRed positive cells. The histogram reports the 
intensity of GFP fluorescence in the MS2-DsRed population. (B) Flow cytometry and gating 
procedure for all β-catenin-responsive devices. As an example, flow cytometry data from the β-
cat-6 device is presented. Dot plots show initial gating of viable stable cells (P1) in the presence 
of water or the LTD4 inducer. The resulting histogram reports the intensity of GFP fluorescence 
in the viable cell population. An identical gating procedure was followed for the flow cytometry 
analysis of the NF-κB-responsive devices. 
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Figure S7. Representative flow cytometry histograms for the MS2-, β-catenin- and NF-κB-
responsive devices 
(A) Representative flow cytometry histograms for the MS2-responsive devices. The histograms 
report the intensity of GFP fluorescence for both the wild-type and mutant MS2-3 and MS2-10 
regulatory devices in the presence of DsRed and MS2-DsRed. The mutant devices show a 
minimal change in GFP fluorescence in the presence of MS2-DsRed, while wild-type devices 
show a significant change in response to MS2-DsRed. The fluorescence data shown here is 
presented in Fig. 1E (B) Representative flow cytometry histograms for the β-catenin-responsive 
devices. The histograms report the intensity of GFP fluorescence for both the wild-type and 
mutant β-cat-6 regulatory devices in the presence of water or LTD4. The mutant device shows a 
minimal change in GFP fluorescence in the presence of LTD4, while the wild-type device shows 
a significant increase in fluorescence in response to LTD4. The fluorescence data shown here is 
presented in Fig. 2F (C) Representative flow cytometry histograms for the NF-κB-responsive 
devices. The histograms report the intensity of GFP fluorescence for both the wild-type and 
mutant p50(1)-3 regulatory devices in the presence of water or TNF-α. The mutant device shows 
a minimal change in GFP fluorescence in the presence of TNF-α, while the wild-type device 
shows a significant decrease in fluorescence in response to TNF-α. The fluorescence data shown 
here is presented in Fig. 2C. 
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Figure S8. Representative flow cytometry gating procedures and histograms for the MS2-3-
Puma apoptosis studies  
(A) Flow cytometry and gating procedure for the MS2-3-Puma device mediated apoptosis. Cells 
were stained with Pacific blue annexin V and 7AAD using the Vybrant Apoptosis Assay Kit 
(Invitrogen) according to the manufacturer’s instructions. The positioning of all gates are based 
on the individual gates established for each single color control and can vary slightly between 
experiments. Dot plots show initial gating of all stable cells (P1), followed by gating for all MS2-
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Venus positive cells. The final gated dot plot reports on the stages of programmed cell death for 
each cell line using a dual parameter staining consisting of Pacific blue annexin V and 7AAD. 
Briefly, live cells are Pacific blue annexin V negative and 7AAD negative, apoptotic cells are 
Pacific blue annexin V positive and 7AAD negative, and dead cells are 7AAD positive. (B) Flow 
cytometry analysis of the MS2-3-Puma devices. The dot plots report on the stages of 
programmed cell death for both the wild-type and mutant MS2-3-Puma regulatory devices in the 
presence of Venus or MS2-Venus. The percentage of apoptotic cells shown here are reported in 
Fig. S5B. 
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Figure S9. Representative flow cytometry gating procedures and histograms for the β-cat-
6-Puma apoptosis studies  
(A) Flow cytometry and gating procedure for the β-cat-6-Puma device mediated apoptosis. Cells 
were stained with Pacific blue annexin V and 7AAD. Dot plots show initial gating of all stable 
cells (P1) and the resulting gated dot plot reports on the stage of programmed cell death for each 
cell line. (B) Flow cytometry analysis of the β-cat-6-Puma devices. The dot plots report on the 
stages of programmed cell death for both the wild-type and mutant β-cat-6-Puma regulatory 
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devices in the presence of water or LTD4. The percentage of apoptotic cells shown here are 
reported in Fig. S5F. The gating procedure shown in panel (A) was followed for the flow 
cytometry analysis of the NF-κB-Puma regulatory devices. 
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Aptamer MS2           MS2∆           
Protein DsRed   
MS2-
DsRed   Expression Excl/incl  DsRed   
MS2-
DsRed   Expression Excl/incl  
Position 
Avg. 
RFU Stdev. 
Avg. 
RFU Stdev. (fold) (fold) 
Avg. 
RFU Stdev. 
Avg. 
RFU Stdev. (fold) (fold) 
1 13.42 0.01 20.47 2.98 1.53 0.76 11.73 1.51 27.34 0.04 2.33 1.00 
2 11.74 0.16 17.19 0.18 1.46 0.90 7.19 0.23 10.21 0.01 1.42 0.97 
3 20.72 0.81 68.35 5.45 3.30 1.57 21.01 2.80 20.02 0.42 0.95 0.50 
4 21.84 0.63 63.19 5.17 2.89 1.19 24.33 0.47 45.44 3.59 1.87 0.81 
5 19.58 1.66 33.44 1.35 1.71 1.19 15.65 0.16 23.46 2.46 1.50 1.37 
6 23.46 2.46 24.21 0.25 1.03 0.59 24.12 5.42 39.83 1.77 1.65 5.66 
7 29.77 0.53 74.42 2.88 2.50 1.41 14.49 0.48 21.96 2.43 1.52 0.73 
8 11.62 0.11 14.82 0.28 1.28 1.32 14.07 0.99 18.83 1.03 1.34 1.37 
9 8.39 0.23 12.61 0.28 1.50 0.62 13.90 1.46 14.05 0.33 1.01 0.55 
10 2.96 0.37 10.44 0.30 3.53 3.03 13.22 0.14 23.62 1.52 1.79 1.19 
11 24.04 0.23 30.60 1.63 1.27 0.25 18.92 0.81 32.10 0.04 1.70 0.73 
12 34.72 3.91 53.80 9.44 1.55 0.50 18.84 0.47 24.47 0.35 1.30 0.68 
 
Table S1. Raw data from flow cytometry and transcript isoform analysis and for the MS2-responsive devices (Fig. 1E). For each 
device, the average relative fluorescence units (RFU) is shown along with the standard deviation (Stdev) between each duplicate 
sample. For each device the fold change in GFP expression (Expression (fold)) and the fold change in the ratio of exon 7 excluded 
isoform levels to exon 7 included isoform levels (Excl/incl (fold)) (as determined by qRT-PCR analysis; Fig. 1E and Fig. S1F) in the 
presence and absence of ligand are shown. 
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Time (h) 0         6         12          
Stimuli Water   
TNF-
α   Expression Water   TNF-α   Expression Water   TNF-α   Expression  
Device 
Avg. 
RFU Stdev. 
Avg. 
RFU Stdev. (fold) 
Avg. 
RFU Stdev. 
Avg. 
RFU Stdev. (fold) 
Avg. 
RFU Stdev. 
Avg. 
RFU Stdev. (fold)  
p50(1)-3 66.59 3.48 66.43 3.88 1.00 79.49 0.00 74.59 1.53 0.94 85.74 4.38 78.45 0.78 0.91  
p50(1)(2)∆-
3 64.13 1.00 64.12 0.90 1.00 77.29 1.15 75.09 1.33 0.97 83.29 1.82 102.49 1.99 1.23  
p50(2)-3 30.70 2.27 30.35 0.28 0.99 33.43 1.50 31.55 0.10 0.94 34.62 0.59 34.20 1.34 0.99  
p65-3 54.26 0.62 51.72 0.89 0.95 56.03 1.56 52.39 1.13 0.94 69.82 5.56 76.70 2.09 1.10  
p65∆-3 35.25 0.30 35.03 0.42 0.99 37.68 1.72 35.10 1.29 0.93 47.21 4.75 44.45 1.20 0.94  
                 
Time (h) 24         36         48           
Stimuli Water   
TNF-
α   Expression Water   TNF-α   Expression Water   TNF-α   Expression Excl/incl  
Device 
Avg. 
RFU Stdev. 
Avg. 
RFU Stdev. (fold) 
Avg. 
RFU Stdev. 
Avg. 
RFU Stdev. (fold) 
Avg. 
RFU Stdev. 
Avg. 
RFU Stdev. (fold) (fold) 
p50(1)-3 93.51 0.00 66.83 0.49 0.71 86.88 1.34 78.88 1.20 0.91 78.45 0.00 73.85 0.26 0.94 0.12 
p50(1)(2)∆-
3 90.70 0.54 98.99 1.61 1.09 102.36 7.70 117.84 1.66 1.15 77.52 1.50 124.40 3.00 1.60 1.27 
p50(2)-3 31.13 0.42 26.52 2.06 0.85 28.82 1.30 16.76 1.43 0.58 30.14 0.80 25.74 2.09 0.85 0.54 
p65-3 64.52 1.57 76.34 2.53 1.18 61.90 3.11 86.23 0.12 1.39 54.96 1.51 104.31 3.30 1.90 1.74 
p65∆-3 41.34 1.01 38.39 1.02 0.93 34.75 1.97 33.36 0.60 0.96 36.79 1.67 30.97 0.61 0.84 0.52 
 
Table S2. Raw data from flow cytometry analysis for the NF-κB-responsive devices (Fig. 2C). The same mutant device (p50(1)(2)∆ -
3) was used for the normalization of the NF-κB p50 device data. For each device, the average relative fluorescence units (RFU) is 
shown along with the standard deviation (Stdev) between each duplicate sample. For each device the fold change in GFP expression 
and the fold change in the ratio of exon 7 excluded isoform levels to exon 7 included isoform levels (Excl/incl) (as determined by 
qRT-PCR analysis at 48 h; Fig. 2C and Fig. S2A) in the presence and absence of ligand are shown. 
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Aptamer p50         p50∆         
Protein DsRed   p50-DsRed Expression DsRed   MS2-DsRed Expression 
Device 
Avg. 
RFU Stdev. 
Avg. 
RFU (fold) (fold) 
Avg. 
RFU Stdev. 
Avg. 
RFU Stdev. (fold) 
p50(1)-3 26.85 1.31 28.94 2.43 1.08 32.40 1.15 51.81 0.34 1.60 
p50(2)-3 18.63 0.57 22.12 0.36 1.19           
 
Table S3. Raw data from flow cytometry analysis for the p50-NF-κB-responsive devices (Fig. 2D). The same mutant device 
(p50(1)(2)∆-3) was used for the normalization of the NF-κB p50 device data. For each device, the average relative fluorescence units 
(RFU) is shown along with the standard deviation (Stdev) between each duplicate sample. For each device the fold change in GFP 
expression in the presence and absence of ligand is shown. 
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Time 
(h) 0         6         12          
Stimuli Water   LTD4   Expression Water   LTD4   Expression Water   LTD4   Expression  
Device 
Avg. 
RFU Stdev. 
Avg. 
RFU Stdev. (fold) 
Avg. 
RFU Stdev. 
Avg. 
RFU Stdev. (fold) 
Avg. 
RFU Stdev. 
Avg. 
RFU Stdev. (fold)  
β-cat-3 39.23 2.21 37.85 0.76 0.96 39.87 2.16 37.31 0.78 0.94 43.00 0.68 41.14 1.22 0.96  
β-cat∆-
3 62.41 4.53 54.60 5.46 0.87 63.42 1.39 73.50 0.05 1.16 67.42 1.30 65.93 2.86 0.98  
β-cat-6 78.74 1.46 80.19 0.93 1.02 86.25 0.18 82.12 0.46 0.95 86.51 1.20 95.23 2.91 1.10  
β-cat∆-
6 64.90 0.37 63.58 5.88 0.98 67.35 1.80 70.86 1.61 1.05 69.14 1.39 69.91 1.51 1.01  
                 
                 
Time 
(h) 24         36         48           
Stimuli Water   LTD4   Expression Water   LTD4   Expression Water   LTD4   Expression Excl/incl  
Device 
Avg. 
RFU Stdev. 
Avg. 
RFU Stdev. (fold) 
Avg. 
RFU Stdev. 
Avg. 
RFU Stdev. (fold) 
Avg. 
RFU Stdev. 
Avg. 
RFU Stdev. (fold) (fold) 
β-cat-3 44.72 0.42 41.76 0.72 0.93 41.76 1.24 37.74 0.47 0.90 35.66 1.51 36.05 0.49 1.01 0.84 
β-cat∆-
3 69.22 2.72 65.42 2.01 0.95 60.04 4.21 56.98 1.63 0.95 47.75 0.21 51.95 0.91 1.09 1.23 
β-cat-6 79.77 0.4 100.33 3.42 1.26 80.93 7.49 104.58 1.06 1.29 80.34 2.67 122.28 2.67 1.52 1.68 
β-cat∆-
6 59.54 1.60 64.93 1.10 1.09 51.53 3.31 44.11 1.36 0.86 53.87 0.07 39.16 0.06 0.73 0.81 
 
Table S4. Raw data from flow cytometry analysis for the β-catenin-responsive devices (Fig. 2F). For each device, the average relative 
fluorescence units (RFU) is shown along with the standard deviation (Stdev) between each duplicate sample. For each device the fold 
change in GFP expression and the fold change in the ratio of exon 7 excluded isoform levels to exon 7 included isoform levels 
(Excl/incl) (as determined by qRT-PCR analysis at 48 h; Fig. 2F and Fig. S2C) in the presence and absence of ligand are shown. 
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Position                         
3 (MS2) WTapt    WTapt     MUTapt     MUTapt     
10 
(MS2) WTapt   Expression MUTapt   Expression WTapt   Expression MUTapt   Expression 
  
Avg. 
RFU Stdev. (fold) 
Avg. 
RFU Stdev. (fold) 
Avg. 
RFU Stdev. (fold) 
Avg. 
RFU Stdev. (fold) 
DsRed 17.17 0.74 1.00 26.73 2.26 1.00 21.47 1.92 1.00 35.44 2.18 1.00 
MS2-
DsRed 37.07 1.48 2.16 44.59 0.91 1.67 31.90 0.28 1.49 36.08 2.45 1.02 
 
Table S5. Raw data from flow cytometry analysis for the MS2 multi-input processing regulatory device (Fig. 3B). For each device, 
the average relative fluorescence units (RFU) is shown along with the standard deviation (Stdev) between each duplicate sample and  
the fold change in GFP expression relative to the absence of ligand (DsRed only). 
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Position                         
3 (p50) WTapt    WTapt     MUTapt     MUTapt     
10 (MS2) WTapt   Expression MUTapt   Expression WTapt   Expression MUTapt   Expression 
  Avg. RFU Stdev. (fold) Avg. RFU Stdev. (fold) Avg. RFU Stdev. (fold) Avg. RFU Stdev. (fold) 
DsRed 4.34 0.03 1.00 18.59 1.31 1.00 5.06 0.00 1.00 18.21 0.56 1.00 
TNF-α 3.99 0.30 0.92 11.73 1.36 0.63 6.92 0.66 1.37 27.73 0.57 1.52 
MS2-DsRed 6.91 0.16 1.59 13.94 0.33 0.75 10.05 0.00 1.99 13.39 0.76 0.74 
TNF-α + DsRed 5.96 0.21 1.37 17.90 1.85 0.96 11.75 0.37 2.32 20.05 2.18 1.10 
TNF-α + MS2-DsRed 22.93 1.11 5.28 11.30 0.23 0.61 13.39 0.76 2.65 18.86 1.23 1.04 
 
Table S6. Raw data from flow cytometry analysis for the MS2 / NF-κB p50 multi-input processing regulatory device (Fig. 3D). For 
each device, the average relative fluorescence units (RFU) is shown along with the standard deviation (Stdev) between each duplicate 
sample and the fold change in GFP expression relative to the absence of ligand (DsRed only).  
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Name Primer sequence (5’ to 3’) 
Ex6 GCGCGCTAGCATGTATTATATGGTAAGTAATCACTCAGC 
Ex8 ATAGCTAGCGCTGCTACCTGCCAGC 
GFP1 GCGCGCTAGCGTGAGCAAGGGCGAG 
GFP2 GCGCGGGCCCTTAGTACAGCTCGTCCATGCC 
Puma1 ATAGTTTAAACGGTGGTTCT GGTGGTTCTGCCCGCGCACGCCAGGAG 
Puma2 GCGC GTTTAAACTTAATTGGGCTCCATCTCGGG 
TK1 GCGCGCTAGCGTGACAGGGGGAATGGC 
TK2 GCGCGTTTAAACTTAGTTAGCCTCCCCCATCTC 
DsRed1 ATAGGATCCGACAACACCGAGGACGTCAT 
DsRed2 ATAGCGGCCGCCTACTGGGAGCCGGAG 
MS2-1 AGCCAAAAAAAAAACGCAAAGTGGCTTCTAACTTTACTCAGTTCGTTC 
MS2-2 ATAGGATCCACCACCACCACCGTAGATGCCG 
MS2-3 ATAGGTACCATGGATTACAAGGATGACGATGACAAGCCAAAAAAAAAAC
GCAAAGTGGCTTCTAACTTTAC 
P50-1 AGCCAAAAAAAAAACGCAAAGTGGCAGAAGATGATCCATATTTGGGAAG                   
P50-2 ATAGGTACCGTCATCACTTTTGTCACAACCTTC 
P50-3 ATAGCTAGCATGGATTACAAGGATGACGATGACAAGCCAAAAAAAAAAC
GCAAAGTGGCAGAAGATGATCC 
SMN1cDNA TAGAAGGCACAGTCGAGG 
Bcat3 ATATGATACTAGCTATCAGGCCGA 
Bcat3∆ ATATGATATCTAGCTATCTCGGTTAG   
Bcat6 ATATATCGATGTCTATATAGCTATTTTTTTTAACTT 
Bcat6∆ ATATATCGATGTCTATATAGCTATTTTTTTTAACTT 
AptRv ATACTCGAGCAGACTTACTCCTTAATTTAAGGAATG 
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p50(1) ATATGATATCTAGCTATCCGCGC 
p50(1)∆ ATATGATATCTAGCTATCCGTAGCC 
p50(2) ATATGATATCTAGCTATCCGCGC 
p65 ATATGATATCTAGCTATCGAAGCTACAAGAAGGACAGCAC      
 
Table S7. Primer sequences used in this work. 
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Name Description 
pCS1773 SM1-GFP. Contains the wild-type SMN1 mini-gene fused to the C-terminus of 
GFP.  
pCS1774 SMN1 mini-gene template 
pCS1775 β-cat-3-GFP. Wild-type SMN1 mini-gene containing the β-catenin aptamer in 
position 3 of intron 6 fused to the C-terminus of GFP. 
pCS1776 β-cat∆-3-GFP. Wild-type SMN1 mini-gene containing the mutant β-catenin 
aptamer in position 3 of intron 6 fused to the C-terminus of GFP. 
pCS1777 β-cat-6-GFP. Wild-type SMN1 mini-gene containing the β-catenin aptamer in 
position 6 of intron 6 fused to the C-terminus of GFP. 
pCS1778 β-cat∆-6-GFP. Wild-type SMN1 mini-gene containing the mutant β-catenin 
aptamer in position 6 of intron 6 fused to the C-terminus of GFP. 
pCS1779 NF-κBp50(1)-3-GFP. Wild-type SMN1 mini-gene containing the NF-κBp50(1) 
aptamer in position 3 of intron 6 fused to the C-terminus of GFP. 
pCS1780 NF-κBp50(1) ∆-3-GFP. Wild-type SMN1 mini-gene containing the mutant NF-
κBp50(1) aptamer in position 3 of intron 6 fused to the C-terminus of GFP. 
pCS1781 NF-κBp50(2)-3-GFP. Wild-type SMN1 mini-gene containing the NF-κBp50(2) 
aptamer in position 3 of intron 6 fused to the C-terminus of GFP. 
pCS1782 NF-κBp65-3-GFP. Wild-type SMN1 mini-gene containing the NF-κBp65 
aptamer in position 3 of intron 6 fused to the C-terminus of GFP. 
pCS1783 NF-κBp65 ∆-3-GFP. Wild-type SMN1 mini-gene containing the mutant NF-
κBp65 aptamer in position 3 of intron 6 fused to the C-terminus of GFP. 
pCS1784 MS2-3-MS2-10. Wild-type SMN1 mini-gene containing the MS2 aptamer in 
position 3 of intron 6 and in position 10 of intron 7 fused to the C-terminus of 
GFP. 
pCS1785 MS2∆-3-MS2-10. Wild-type SMN1 mini-gene containing the mutant MS2 
aptamer in position 3 of intron 6 and the wild-type MS2 aptamer in position 10 of 
intron 7 fused to the C-terminus of GFP. 
pCS1786 MS2-3-MS2∆-10. Wild-type SMN1 mini-gene containing the wild-type MS2 
aptamer in position 3 of intron 6 and the mutant MS2 aptamer in position 10 of 
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intron 7 fused to the C-terminus of GFP. 
pCS1787 MS2∆-3-MS2∆-10. Wild-type SMN1 mini-gene containing the mutant MS2 
aptamer in position 3 of intron 6 and in position 10 of intron 7 fused to the C-
terminus of GFP. 
pCS1788 NF-κBp65-3-MS2-10. Wild-type SMN1 mini-gene containing the NF-κBp65 
aptamer in position 3 of intron 6 and the MS2 aptamer in position 10 of intron 7 
fused to the C-terminus of GFP. 
pCS1789 NF-κBp65∆-3-MS2-10. Wild-type SMN1 mini-gene containing the mutant NF-
κBp65 aptamer in position 3 of intron 6 and the MS2 aptamer in position 10 of 
intron 7 fused to the C-terminus of GFP. 
pCS1790 NF-κBp65-3-MS2∆-10. Wild-type SMN1 mini-gene containing the NF-κBp65 
aptamer in position 3 of intron 6 and the mutant MS2 aptamer in position 10 of 
intron 7 fused to the C-terminus of GFP. 
pCS1791 NF-κBp65∆-3-MS2∆-10. Wild-type SMN1 mini-gene containing the mutant NF-
κBp65 aptamer in position 3 of intron 6 and the mutant MS2 aptamer in position 
10 of intron 7 fused to the C-terminus of GFP. 
pCS1792 Puma. Contains Puma in pcDNA5/FRT. 
pCS1793 MS2-3. Wild-type SMN1 mini-gene containing the MS2 aptamer in position 3 of 
intron 6 fused to the C-terminus of GFP. 
pCS1794 MS2∆-3. Wild-type SMN1 mini-gene containing the mutant MS2 aptamer in 
position 3 of intron 6 fused to the C-terminus of GFP. 
pCS1795 MS2-3-Puma.  Wild-type SMN1 mini-gene containing the MS2 aptamer in 
position 3 of intron 6 fused to the C-terminus of Puma. 
pCS1796 MS2∆-3-Puma.  Wild-type SMN1 mini-gene containing the mutant MS2 aptamer 
in position 3 of intron 6 fused to the C-terminus of Puma. 
pCS1797 β-cat-6-Puma. Wild-type SMN1 mini-gene containing the β-catenin aptamer in 
position 6 of intron 6 fused to the C-terminus of Puma. 
pCS1798 β-cat∆-6-Puma. Wild-type SMN1 mini-gene containing the mutant β-catenin 
aptamer in position 6 of intron 6 fused to the C-terminus of Puma. 
pCS1799 p65-3-Puma. Wild-type SMN1 mini-gene containing the NF-κB p65 aptamer in 
position 3 of intron 6 fused to the C-terminus of Puma. 
40 
 
pCS1800 p65∆-3-Puma. Wild-type SMN1 mini-gene containing the mutant NF-κB p65 
aptamer in position 3 of intron 6 fused to the C-terminus of Puma. 
pCS1801 HSV-TK. Contains HSV-TK in pcDNA5/FRT. 
pCS1802 β-cat-6-TK. Wild-type SMN1 mini-gene containing the β-catenin aptamer in 
position 6 of intron 6 fused to the C-terminus of HSV-TK. 
pCS1803 β-cat∆-6-TK. Wild-type SMN1 mini-gene containing the mutant β-catenin 
aptamer in position 6 of intron 6 fused to the C-terminus of HSV-TK. 
pCS1804 p65-3-TK. Wild-type SMN1 mini-gene containing the NF-κB p65 aptamer in 
position 3 of intron 6 fused to the C-terminus of HSV-TK. 
pCS1805 p65∆-3-TK. Wild-type SMN1 mini-gene containing the mutant NF-κB p65 
aptamer in position 3 of intron 6 fused to the C-terminus of HSV-TK. 
pCS1392 MS2-DsRed. Contains the FLAG-NLS-MS2 gene fused to the C-terminus of 
DsRed. 
pCS1806 NF-κBp50-DsRed. Contains the FLAG-NLS-NF-κBp50 gene fused to the C-
terminus of DsRed. 
pCS1807 MS2-Venus. Contains the FLAG-NLS-MS2 gene fused to the C-terminus of 
Venus. 
pCS1808 Venus. Contains Venus in pcDNA5/FRT. 
 
Table S8. Plasmid constructs used in this work. 
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Name Position Restriction 
sites 
Cassette (5’-3’) 
MS2-1 1 Kpn I/Cla I ATATGGTACCAACACGTACACCATCAGGGTACGT
CCATATAAAGCTATAGATATCTAGCTATCGATA
TAT 
MS2∆-1 1 Kpn I/Cla I ATATGGTACCAACACGTACCCATCAGGGTACGTC
CATATAAAGCTATAGATATCTAGCTATCGATAT
AT 
MS2-2 2 Kpn I/Cla I ATATGGTACCAACATCCATATAAAGCTATCGTA
CACCATCAGGGTACGAGATATCTAGCTATCGATT
AT 
MS2∆-2 2 Kpn I/Cla I ATATGGTACCAACATCCATATAAAGCTATCGTA
CCCATCAGGGTACGAGATATCTAGCTATCGATTA
T 
MS2-3 3 Eco RV/Xho I ATATGATATCTAGCTATCCGTACACCATCAGGGT
ACGGATGTCTATATAGCTATTTTTTTTAACTTCC
TTTATTTTCCTTACAGGGTTTCAGACAAAATCA
AAAAGAAGGAAGGTGCTCACATTCCTTAAATTA
AGGAGTAAGTCTGCTCGAGATAT 
MS2∆-3 3 Eco RV/Xho I ATATGATATCTAGCTATCCGTACCCATCAGGGTA
CGGATGTCTATATAGCTATTTTTTTTAACTTCCT
TTATTTTCCTTACAGGGTTTCAGACAAAATCAA
AAAGAAGGAAGGTGCTCACATTCCTTAAATTAA
GGAGTAAGTCTGCTCGAGATAT 
MS2-4 4 Cla I/Xho I ATATATCGATGTCTATATAGCTCGTACACCATCA
GGTACGATTTTTTTTAACTTCCTTTATTTTCCTTA
CAGGGTTTCAGACAAAATCAAAAAGAAGGAAG
GTGCTCACATTCCTTAAATTAAGGAGTAAGTCT
GCTCGAGATAT 
MS2∆-4 4 Cla I/Xho I ATATATCGATGTCTATATAGCTCGTACCCATCAG
GGTACGATTTTTTTTAACTTCCTTTATTTTCCTTA
CAGGGTTTCAGACAAAATCAAAAAGAAGGAAG
GTGCTCACATTCCTTAAATTAAGGAGTAAGTCT
GCTCGAGATAT 
MS2-5 5 Cla I/Xho I ATATATCGATGTCTATATAGCTATTTTTTTTAAC
TTCCGTACACCATCAGGGTACGCTTTATTTTCCTT
ACAGGGTTTCAGACAAAATCAAAAAGAAGGAA
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GGTGCTCACATTCCTTAAATTAAGGAGTAAGTC
TGCTCGAGATAT 
MS2∆-5 5 Cla I/Xho I ATATATCGATGTCTATATAGCTATTTTTTTTAAC
TTCCGTACCCATCAGGGTACGCTTTATTTTCCTTA
CAGGGTTTCAGACAAAATCAAAAAGAAGGAAG
GTGCTCACATTCCTTAAATTAAGGAGTAAGTCT
GCTCGAGATAT 
MS2-6 6 Cla I/Xho I ATATATCGATGTCTATATAGCTATTTTTTTTAAC
TTCCTTTATTTTCCTTACCGTACACCATCAGGGTA
CGAGGGTTTCAGACAAAATCAAAAAGAAGGAA
GGTGCTCACATTCCTTAAATTAAGGAGTAAGTC
TGCTCGAGATAT 
MS2∆-6 6 Cla I/Xho I ATATATCGATGTCTATATAGCTATTTTTTTTAAC
TTCCTTTATTTTCCTTACCGTACCCATCAGGGTAC
GAGGGTTTCAGACAAAATCAAAAAGAAGGAAG
GTGCTCACATTCCTTAAATTAAGGAGTAAGTCT
GCTCGAGATAT 
MS2-7 7 Cla I/Xho I ATATATCGATGTCTATATAGCTATTTTTTTTAAC
TTCCTTTATTTTCCTTACAGGGTTTCAGACAAAA
TCAAAAAGAAGGAAGGTGCTCACATTCCTTAAA
TTAAGGAGTAAGTCTGCGTACACCATCAGGGTAC
GCTCGAGATAT 
MS2∆-7 7 Cla I/Xho I ATATATCGATGTCTATATAGCTATTTTTTTTAAC
TTCCTTTATTTTCCTTACAGGGTTTCAGACAAAA
TCAAAAAGAAGGAAGGTGCTCACATTCCTTAAA
TTAAGGAGTAAGTCTGCGTACCCATCAGGGTACG
CTCGAGATAT 
MS2-8 8 Xho I/HindIII ATATCTCGAGCCAGCATTACGTACACCATCAGGG
TACGTGAAAGTGAATCTTACTTTTGTAAAAAAG
CTTATAT 
MS2∆-8 8 Xho I/HindIII ATATCTCGAGCCAGCATTACGTACCCATCAGGGT
ACGTGAAAGTGAATCTTACTTTTGTAAAAAAGC
TTATAT 
MS2-9 9 Xho I/HindIII ATATCTCGAGCCAGCATTATGAAAGTGAATCTT
ACGTACACCATCAGGGTACGCTTTTGTAAAAAAG
CTTATAT 
MS2∆-9 9 Xho I/HindIII ATATCTCGAGCCAGCATTATGAAAGTGAATCTT
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ACGTACCCATCAGGGTACGCTTTTGTAAAAAAGC
TTATAT 
MS2-10 10 Xho I/Bam HI ATATCTCGAGCCAGCATTATGAAAGTGAATCTT
ACTTTTGTAAAAAAGCCGTACACCATCAGGGTAC
GTTCTTTATGGTTTGTGGGATCCATAT 
MS2∆-10 10 Xho I/Bam HI ATATCTCGAGCCAGCATTATGAAAGTGAATCTT
ACTTTTGTAAAAAAGCCGTACCCATCAGGGTACG
TTCTTTATGGTTTGTGGGATCCATAT 
MS2-11 11 HindIII/Bam 
HI 
ATATAAGCTTCTTTATGGTTTGTCGTACACCATC
AGGGTACGGGGATCCATAT 
MS2∆-11 11 HindIII/Bam 
HI 
ATATAAGCTTCTTTATGGTTTGTCGTACCCATCA
GGGTACGGGGGATCCATAT 
MS2-12 12 Bam HI/Xba I ATATGGATCCAAATGTTTCGTACACCATCAGGGT
ACGTTGAACAGTTAATCTAGAATAT 
MS2∆-12 12 Bam HI/Xba I ATATGGATCCAAATGTTTCGTACCCATCAGGGTA
CGTTGAACAGTTAATCTAGAATAT 
β-cat-3 3 Eco RV/Xho I ATATGATATCTAGCTATCAGGCCGATCTATGGAC
GCTATAGGCACACCGGATACTTTAACGATTGGCTG
ATGTCTATATAGCTATTTTTTTTAACTTCCTTTA
TTTTCCTTACAGGGTTTCAGACAAAATCAAAAA
GAAGGAAGGTGCTCACATTCCTTAAATTAAGGA
GTAAGTCTGCTCGAGATAT 
β-cat∆-3 3 Eco RV/Xho I ATATGATATCTAGCTATCTCGGTTAGCAATTTCAT
AGGCCACACGGATATCGCAGGTATCTAGCCGGAG
ATGTCTATATAGCTATTTTTTTTAACTTCCTTTA
TTTTCCTTACAGGGTTTCAGACAAAATCAAAAA
GAAGGAAGGTGCTCACATTCCTTAAATTAAGGA
GTAAGTCTGCTCGAGATAT 
β-cat-6 6 Cla I/Xho I ATATATCGATGTCTATATAGCTATTTTTTTTAAC
TTCCTTTATTTTCCTTACAGGCCGATCTATGGACG
CTATAGGCACACCGGATACTTTAACGATTGGCTAG
GGTTTCAGACAAAATCAAAAAGAAGGAAGGTG
CTCACATTCCTTAAATTAAGGAGTAAGTCTGCT
CGAGATAT 
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β-cat∆-6 6 Cla I/Xho I ATATATCGATGTCTATATAGCTATTTTTTTTAAC
TTCCTTTATTTTCCTTACTCGGTTAGCAATTTCATA
GGCCACACGGATATCGCAGGTATCTAGCCGGAAG
GGTTTCAGACAAAATCAAAAAGAAGGAAGGTG
CTCACATTCCTTAAATTAAGGAGTAAGTCTGCT
CGAGATAT 
 
NF-κBp50(1)-3 3 Eco RV/Xho I ATATGATATCTAGCTATCGCATCCTGAAACTGTTT
TAAGGTTGGCCGATGCGATGTCTATATAGCTATT
TTTTTTAACTTCCTTTATTTTCCTTACAGGGTTTC
AGACAAAATCAAAAAGAAGGAAGGTGCTCACA
TTCCTTAAATTAAGGAGTAAGTCTGCTCGAGAT
AT 
NF-κBp50(1)∆-3 3 Eco RV/Xho I ATATGATATCTAGCTATCCGTAGCCGGTTGGAAT
TTTGTCAAAGTCCTACGGATGTCTATATAGCTATT
TTTTTTAACTTCCTTTATTTTCCTTACAGGGTTTC
AGACAAAATCAAAAAGAAGGAAGGTGCTCACA
TTCCTTAAATTAAGGAGTAAGTCTGCTCGAGAT
AT 
NF-κBp50(2)-3 3 Eco RV/Xho I ATATGATATCTAGCTATCCGCGCGATCTTGAAAC
TGTTTTAAGGTTGGCCGATCGCGCGGATGTCTAT
ATAGCTATTTTTTTTAACTTCCTTTATTTTCCTTA
CAGGGTTTCAGACAAAATCAAAAAGAAGGAAG
GTGCTCACATTCCTTAAATTAAGGAGTAAGTCT
G CTCGAGATAT 
NF-κBp65-3 3 Eco RV/Xho I GAAGCTTACAAGAAGGACAGCACGAATAAAACCTG
CGTAAATCCGCCCCATTTGTGTAAGGGTAGTGGGT
CGAATTCCGCTCAGATGTCTATATAGCTATTTTTT
TTAACTTCCTTTATTTTCCTTACAGGGTTTCAGA
CAAAATCAAAAAGAAGGAAGGTGCTCACATTC
CTTAAATTAAGGAGTAAG 
NF-κBp65∆-3 3 Eco RV/Xho I ACTCGCCTTAAGCTGGGTGATGGGAATGTGTTTAC
CCCGCCTAAATGCGTCCAAAATAAGCACGACAGGA
AGAACATTCGAAGGATGTCTATATAGCTATTTTTT
TTAACTTCCTTTATTTTCCTTACAGGGTTTCAGA
CAAAATCAAAAAGAAGGAAGGTGCTCACATTC
CTTAAATTAAGGAGTAAG 
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Table S9. Aptamer cassette sequences used in the construction of the RNA devices. Aptamer 
sequences are italicized and nucleotides added for strengthening aptamer secondary structure are 
in red. 
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Name Forward Primer (5’ - 3’) Reverse Primer (5’ - 3’) Isoform 
 
Pair 1 GTATTATATGGAAATGCTGG GAA GGTGGTCACGAGGG Ex6/8 and GFP 
Pair 2 TAAATTAAGGAGAAATGCT GAA GGTGGTCACGAGGG Ex7/8 and GFP 
Pair 3 CAAAGATGGTCAAGGTCGCAAG GGCGATGTCAATAGGACTCC HPRT 
 
Table S10. Primer sequences for transcript isoform analysis through qRT-PCR. 
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